1 active not recruiting, 1 completed, 1 recruiting. 2 Phase 2, 1 Early Phase 1, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
| Early Phase 1 | 1 | Completed 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine: new trials by email Literature Review of Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine trials Research Report on Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial Biopsy, Biospecimen Collection, Computed Tomography - Advanced Fallopian Tube Carcinoma, Advanced Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Recruiting | Mayo Clinic | 78 | 2024-11-12 | 2026-10-02 |
| Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Biopsy, Biospecimen Collection, Computed Tomography - Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 38 | 2023-09-28 | 2026-09-21 |
| Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor | Early Phase 1 | Completed | Mayo Clinic | 19 | 2014-04-14 | 2025-10-31 |
Fallopian Tube Neoplasms (2) · Ovarian Neoplasms (2)
Mayo Clinic (3)
United States (3)
Matthew S. Block, MD, PhD (2) · Matthew S. Block, M.D., Ph.D. (1)
P50CA136393 (1), R01CA276313 (1)